ASH 2021 | Updates on maintenance therapies in AML
In this video, Jan Philipp Bewersdorf, MD, Yale University, New Haven, CT, gives a detailed overview on maintenance therapies in acute myeloid leukemia (AML). First, Dr Bewersdorf mentions the importance of considering the context in which AML maintenance therapies are discussed: maintenance therapy after allogeneic transplant vs maintenance therapy after induction chemotherapy. In the first context, Dr Bewersdorf reports on advances in the use of FLT3 inhibitors, drawing focus on sorafenib and its benefits and drawbacks. Following this, Dr Bewersdorf discusses advances in the use of hypomethylating agents (HMAs) in AML, reporting on clinical trials that have used both injectable azacitidine (AZA) and oral azacitidine (CC-486) in treatment. To conclude, Dr Bewersdorf then draws focus on trial updates and findings from the QUAZAR AML-001 trial (NCT01757535) and the future of research in this area. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
